5:30 PM
 | 
Feb 15, 2013
 |  BC Extra  |  Clinical News

Amicus falls on Phase III Fabry's subgroup data

Amicus Therapeutics Inc. (NASDAQ:FOLD) fell $1 (26%) to $2.89 on Friday after reporting post hoc subgroup data from Fabry's disease patients based on baseline disease burden in the Phase III FACETS (Study 011) trial of Amigal migalastat. In 35 patients with a lower disease burden, 32% of patients receiving Amigal achieved a 50% or greater reduction in kidney interstitial capillary globotriaosylceramide (GL-3) levels as measured in kidney...

Read the full 335 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >